FDA PreCheck pilot picks Eli Lilly and Regeneron for faster review of new manufacturing sites

The FDA has selected Eli Lilly and Company and Regeneron Pharmaceuticals as participants in a pilot effort under the agency’s “PreCheck” program, according to coverage published June 30 by Yahoo Finance.

PreCheck is designed to streamline part of the manufacturing approval process by allowing the FDA to evaluate certain information about facilities while construction is still underway. The concept is to reduce time spent on later-stage back-and-forth by identifying issues earlier in the build cycle, before a site is ready for production.

In the coverage, the FDA estimates the pilot could save participating companies up to 14 months. That estimate is tied specifically to reviewing facilities while they are still under construction, rather than waiting until after completion.

For Eli Lilly, the implication is straightforward: the company could potentially improve timing for getting new or expanded manufacturing capacity online, particularly for complex biologics that typically require tightly controlled processes and documentation. More predictable facility readiness can matter for meeting planned supply timelines and for reducing the risk that production start dates slip due to avoidable compliance findings.

Regeneron’s participation points to similar operational stakes. As sponsors plan manufacturing footprint changes and scale-up activity, earlier facility review could be a lever for compressing schedules and tightening coordination between construction, validation, and regulatory readiness.

Industry-wide, FDA PreCheck sits within a broader push to modernize and accelerate development and approval pathways. While facility review remains a compliance-critical step, programs that shift portions of the assessment earlier can change project management dynamics, especially when a company is building new space or significantly modifying existing sites.

The post does not provide additional detail on what specific facilities will be reviewed under PreCheck, which product lines are involved, or whether the participating companies will be subject to a fully defined set of review milestones. It also does not say how the pilot results will be measured or when the FDA expects to expand the program beyond participants.

For market watchers, the key near-term question is how quickly the FDA’s facility assessments translate into downstream approvals or production timelines. It is also worth watching for any additional disclosures from the companies about which sites are included and how they view PreCheck in the context of their near-term manufacturing plans.